Home > News > Latest > Matrix Medical Network Announces Sale of Decentralized Clinical Trials Service Line to Emvenio Research

Health Technology

Matrix Medical Network Announces Sale of Decentralized Clinical Trials Service Line to Emvenio Research

Matrix Medical Network® and Emvenio Research® announced the sale of the Matrix Clinical Trials service line to Emvenio, a leading decentralized clinical trials company. The transaction will provide Emvenio with proven DCT capabilities, while allowing Matrix to focus on improving the health and wellness of health plan members, and keeping America's workers productive and safe, through its design of custom and flexible clinical solutions. Post transaction, Emvenio will deploy additional resources, technology, and capital to continue to grow and scale its clinical trials services both domestically and internationally, making clinical research more accessible, equitable, and effective.

"At the onset of the pandemic Matrix mobilized quickly to provide decentralized clinical trial solutions in support of vaccine and therapy development for COVID-19. We leveraged our skilled clinicians, Mobile Health Clinics, and experienced leaders to adapt traditional clinical trials protocols to better reach and recruit diverse, underserved, and high-risk patients. We are incredibly proud of the remarkable work the Matrix Clinical Trials team started during the pandemic and continued to expand upon. I am excited about this transition and look forward to watching the leaders and employees of Emvenio continue to develop and deliver decentralized clinical trial solutions that best serve those patients who most need access to new treatments."

Catherine J. Tabaka, Matrix Chief Executive Officer

"The leaders of Matrix Clinical Trials showed leadership, agility, creativity, and perseverance in building a decentralized clinical trial organization from the ground up," said Keith Henthorne, Emvenio Chief Executive Officer. "I look forward to working closely with these leaders in order to build upon this solid foundation established by Matrix and to continue making clinical trials more accessible to diverse populations throughout the world. To ensure continued access to clinical trials for the patients who need it most, many Matrix employees and leaders will be a part of the Emvenio team going forward. I am proud to be working alongside strong leaders like Dr. Daniel Castillo and Thad Wolfram, amongst others, and look forward to growing the company with them."

About Matrix Medical Network
Matrix Medical Network has provided expert care and health services to millions of at-risk individuals where they live and work for more than 20 years. The organization's network of approximately 4,000 clinicians meets individuals wherever they are, to assess their health and safety, identify and close care gaps, and offer life-changing services that activate them to manage their own health.

About Emvenio
Emvenio is a leading decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Its mission is to eliminate the barriers to clinical trials by engaging with people in their communities and in their homes. Emvenio's technology enabled, innovative network of Mobile Research Sites, At Home Visits, and Virtual Visits are a unique blend of global DCT capabilities that can be deployed to better reach, recruit and retain diverse patient populations, while improving the clinical trial experience. These capabilities offer global DCT participant-centric approaches that provide flexibility, meet the most challenging clinical trial demands, and provide convenience for patients and caregivers in a compliant manner. Emvenio is transforming how all stakeholders engage in, experience, and deliver clinical research.

Spotlight

Other News

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Health Technology

Home Care Delivered, Inc. Completes Acquisition of Medline Industries, LP's DMEPOS Supplier Business Unit

PR Newswire | October 17, 2023

Home Care Delivered, Inc. a leader in providing medical supplies including diabetes/CGM, incontinence, wound, urological, and ostomy products, is excited to announce the successful acquisition of Medline Industries, LP's DMEPOS supplier business unit. This strategic move will significantly enhance HCD's market presence, expand its geographical footprint, and provide access to a broader customer base while reinforcing relationships with patients, healthcare plans and providers, and manufacturers. "The transaction represents a major milestone for HCD by leveraging over 25 years of distinguished expertise in medical supplies," said Gordy Fox, founder and chief executive officer of HCD. "This acquisition aligns with our commitment to delivering personalized and compassionate customer experiences while leveraging Medline's DMEPOS supplier assets, and continuing to provide our industry expertise and best-in-class customer service." said Brad Mariam, executive vice president, Medline. With the transition of Medline's DMEPOS supplier assets to HCD, a company that shares in our commitment to exceptional service and patient care, Medline will continue to focus on its core role as an industry leader in the manufacturing and distribution of quality medical supplies. [Source: PR Newswire] "By integrating Medline's DMEPOS supplier assets, we are accelerating our growth strategy, delivering an avenue for expanded cost-efficiencies and member adherence," said Lowell Price, senior vice president of business development and chief growth officer of HCD. "This strategic move aligns with our commitment to delivering superior customer service, additional product offerings and ensuring reliable delivery to our members. HCD is well-positioned to continue to elevate customer experiences and reinforce our market presence." About Home Care Delivered, Inc. Home Care Delivered is a leading direct-to-consumer provider of insurance-covered medical supplies of diabetes testing, incontinence, urology, ostomy and wound care supplies delivered directly to the patient's home. Founded in 1996 and headquartered in Glen Allen, Virginia, Home Care Delivered is dedicated to providing best-in-class customer support and quality supplies for patients and caregivers nationwide.

Health Technology, Healthcare Analytics

Weave Partners with Affirm to Expand Payment Options for Patients

businesswire | September 27, 2023

Weave a leading all-in-one experience platform for small and medium-sized healthcare businesses, announced a new partnership with Affirm the payment network that empowers consumers and helps merchants drive growth. Now available to thousands of Weave’s customers, this collaboration provides flexible payment options for eligible patients, making it easier for them to access and afford the care they need. By partnering with Affirm, Weave customers can offer their patients pay-over-time financing with as low as 0% APR. Affirm is directly integrated with Weave payments, so patients can apply to pay with Affirm in a matter of seconds, and spread out their payments over time, easing the burden of upfront costs and providing an additional payment option for dental, optometry, veterinary, or medical practices. This partnership will not only benefit patients but also allow healthcare practices to receive payments quicker than before. “Collecting payments is one of the most important parts of the patient's journey. A smooth and efficient payment process can help to create a positive patient experience, build trust, and encourage repeat business, which is why we are excited to partner with Affirm,” said Branden Neish, Chief Product & Technology Officer of Weave. “By providing more flexible and affordable payment options, we are empowering patients to take control of their healthcare and ensuring that cost doesn’t prevent them from receiving the care they need.” By expanding the payment options available to patients, Weave and Affirm aim to remove barriers to care and ensure everyone has access to the healthcare services they need. The partnership reflects the shared commitment of both companies to make patients’ payment experience more seamless and revolutionize the way healthcare practices handle payments. “By partnering with Weave, thousands of healthcare practices can now seamlessly add Affirm’s transparent and flexible payment options at checkout,” said Wayne Pommen, Chief Revenue Officer of Affirm. Patients are eager to pay over time without junk fees, late fees, or compounding interest, and now these businesses can address that demand. [Source – Business Wire] About Weave Weave is the all-in-one experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software. About Affirm Affirm’s mission is to deliver honest financial products that improve lives. By building a new kind of payment network — one based on trust, transparency and putting people first — we empower millions of consumers to spend and save responsibly, and give thousands of businesses the tools to fuel growth. Unlike most credit cards and other pay-over-time options, we show consumers exactly what they will pay up front, never increase that amount, and never charge any late or hidden fees.

Digital Healthcare

Syra Health Announces the Launch of CarePlus, the Company's Electronic Medical Record System

PR Newswire | October 20, 2023

Syra Health Corp. a healthcare company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the launch of CarePlus, its own Electronic Medical Record (EMR) system designed specifically for small to mid-sized healthcare organizations. CarePlus is an easy-to-use, secure, and scalable platform that allows for streamlining clinical workflows and integrating telehealth. said Sandeep Allam, Executive Chairman, President, and Digital Health Leader, Syra Health. We listened to what healthcare providers were telling us they wanted in their EMR system. We are proud to offer CarePlus, our affordable solution that can be further customized to fit each organization's individual needs. [Source –PR Newswire] Another unique feature of CarePlus is its ability to interact with labs, radiology systems, and other EMRs, eliminating interoperability issues. "Our Syra Health developers have created CarePlus that solves a common complaint heard across the healthcare industry about EMR Systems," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "They haven't been able to talk to one another seamlessly until now." AboutSyra Health Corp. Syra Health is a healthcare company with a mission to improve healthcare by providing innovative services and technology solutions. Syra Health aims to achieve its goal by becoming a valuable partner to government, payers, providers, life sciences organizations, and academic institutions. Syra Health offers products and services in digital health, behavioral and mental health, population health management, health education, and healthcare workforce.